Background: Emulsomes are a type of lipid-based nanoparticle that consists of a solid lipid core surrounded by a phospholipid bilayer and have shown promise as drug delivery systems for a variety of applications. The major advantageous aspect of employing lipid-based carriers is their ability to enhance the solubility and bioavailability of poorly water-soluble drugs, mandatorily in case of intranasal drug delivery. These structures have portrayed significant ability to encapsulate drug with poor water solubility and low oral bioavailability, further leading to a completely enhanced drug delivery systems for achieving stability and controlled release of drug. The selection of lipid components and their physiochemical properties can be tailored to optimize drug solubility, blood brain barrier permeability, and enhanced targeting. Main body of Intranasal drug delivery systems offer several advantages over other routes of administration. Intranasal delivery of drugs can provide rapid and efficient absorption into the bloodstream, bypassing first-pass metabolism in the liver and potentially reducing the risk of systemic side effects. Nasal mucosa comprises of dense network of blood vessels, that allow much enhanced rapid drug absorption and direct systemic delivery once the medication is being insufflated through the nasal route. Emulsomes can be used to encapsulate a wide range of drugs, including hydrophobic compounds that are difficult to formulate using traditional delivery methods. By incorporating targeting ligands or other components into the emulsome structure, it is possible to create formulations that are highly selective for specific tissues or cells. The characterization parameters majorly particle size, zeta potential, and encapsulation efficiency play a significant role while demonstrating the effectiveness of emulsome formulation and further its nasal route of administration. Therefore, by assessing and evaluating the parameters, researchers could effectively gain insights into the quality, stability, and enhanced therapeutic effects of emulsome drug carrier, leading to impactful information which would help in future intranasal emulsome preparation preparations, optimization and ensuring the overall effectiveness of the drug delivery systems. Short conclusion: This review discusses the idea of emulsomes drug delivery systems, reviews the effectiveness of emulsomes for the delivery of small molecules, and pays particular attention to its structural and formulation design including benefits of intranasal emulsome delivery with recent advancements, stability aspects, and various considerations related to drug delivery and comprising of future prospects.
The purpose of the current study was to prepare and evaluate a citronella oil-loaded microemulsion-based micro-emulgel for the treatment of Candida albicans. The primary objective was to use the skin to transfer hydrophobic medications into the bloodstream. The formulation included cinnamon oil as an antifungal oil and citronella oil as an active pharmaceutical ingredient, respectively. Tween 80 and PEG 200 were used as the surfactant and co-surfactant, respectively, to create phase diagrams. Carbopol 940, one of the frequently used polymers, was investigated for its ability to prepare gel formulations. The optimized (F3) batch contained the highest percentage (87.05 ± 0.03%) of drug content and, according to the statistics provided, had the highest drug release rate of around 87.05% within 4 h. The Korsmeyer–Peppas model with n value of 0.82, which is in the range 0.5–1, had the highest r2 value, indicating that release following non-Fickian/anomalous diffusion provided a better dimension for all of the formulations. The optimized (F3) formulation had stronger antifungal activity in comparison to other formulations. This leads to the conclusion that citronella oil can be made into a micro-emulgel, which may improve its release in aqueous systems while maintaining a high level of drug release at the target site.
Contact lenses (CLs) have become an essential tool in ocular drug delivery, providing effective treatment options for specific eye conditions. In recent advancements, Therapeutic CLs (TCLs) have emerged as a promising approach for maintaining therapeutic drug concentrations on the eye surface. TCLs offer unique attributes, including prolonged wear and a remarkable ability to enhance the bioavailability of loaded medications by more than 50%, thus gaining widespread usage. They have proven beneficial in pain management, medication administration, corneal healing, and protection. To achieve sustained drug delivery from TCLs, researchers are exploring diverse systems, such as polymeric nanoparticulate systems, lipidic systems, and the incorporation of agents like vitamin E or rate-limiting polymers. However, despite breakthrough successes, certain challenges persist, including ensuring drug stability during processing and manufacturing, controlling release kinetics, and biomaterial interaction, reducing protein adhesion, and addressing drug release during packaging and storage etc. While TCLs have shown overall success in treating corneal and ocular surface disorders, careful consideration of potential issues and contraindications is vital. This review offers an insightful perspective on the critical aspects that need to be addressed regarding TCLs, with a specific emphasis on their advantages and limitations.
1 October 2024 in Nanoscience & Nanotechnology-Asia
The capability of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. The potential of lipid-based nanoparticles (LBNs) to revolutionise cancer therapy is examined in this article. Before moving on to the formulation, characterization, and therapeutic applications of LBN, a brief discussion of the importance of targeted drug delivery is given. Liposomal delivery systems (LBNs), incorporating solid lipid nanoparticles (SLNs), liposomes and nanostructured lipid carriers, offer a versatile platform for accurate drug delivery (NLCs). The article discusses the potential of liquid nanoparticles (LBNs) in cancer therapy, highlighting their stability, storage, and techniques like reverse phase evaporation, thin-film hydration, and microemulsions. It also explores their physical characteristics, drug release studies, and role in tailored treatments. The review highlights manufacturing challenges and regulatory concerns while highlighting the evolving field of LBN applications.
24 July 2025 in International Journal of Biological Macromolecules